Anticancer properties of the novel nitric oxide-donating compound (<i>S,R</i>)-3-phenyl-4,5-dihydro-5-isoxazole acetic acid-nitric oxide <i>in vitro</i> and <i>in vivo</i>
Danijela Maksimović‐Ivanić(Institute for Biological Research “Siniša Stanković”), Stanislava Stošić‐Grujičić(Institute for Biological Research “Siniša Stanković”), Graziella Malaponte(University of Catania), Ljubica Harhaji‐Trajkovic(University of Belgrade), Gianni Garotta(Roche (Switzerland)), Katia Mangano(University of Catania), Djordje Miljković(University of Belgrade), Sanja Mijatović(University of Belgrade), Kai Cheng(Chinese Academy of Sciences), Yousef Al‐Abed(Feinstein Institute for Medical Research), Darrin Dabideen, Ferdinando Nicoletti(University of Catania), Massimo Libra(University of Catania)
Cited by 74
Related Papers
Natural products in drug discovery: advances and opportunities
|Nature Reviews Drug Discovery|2021|5.2k
Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium
|Frontiers in Pharmacology|2018|878
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health
|Oncotarget|2011|579
GSK-3 as potential target for therapeutic intervention in cancer
|Oncotarget|2014|508